Cite

HARVARD Citation

    Czarnecka, A. et al. (2015). Feasibility, efficacy and safety of tyrosine kinase inhibitor treatment in hemodialyzed patients with renal cell cancer: 10 years of experience. Future oncology. pp. 2267-2282. [Online]. 
  
Back to record